- In November 2021, Asuragen, Inc., a Bio-Techne brand, launched a new kit to detect pathogenic variants in the CFTR gene, the AmplideX PCR/CE CFTR kit, for research use only. It covers a larger proportion of the diverse US population than any other commercially available targeted CFTR testing assay. Such products, which are primarily aimed at the American market, are also propelling market growth.
- In December 2020, Taysha Gene Therapies, Inc. signed a lease agreement to occupy and configure a commercial-scale current Good Manufacturing Practices (cGMP) manufacturing facility in Durham, North Carolina for preclinical, clinical, and commercial production of its gene therapy pipeline.
